MCID: KWS002
MIFTS: 72

Kawasaki Disease

Categories: Genetic diseases, Rare diseases, Immune diseases, Cardiovascular diseases, Bone diseases

Aliases & Classifications for Kawasaki Disease

MalaCards integrated aliases for Kawasaki Disease:

Name: Kawasaki Disease 53 12 49 24 55 71 36 51 40 3 14 59
Mucocutaneous Lymph Node Syndrome 53 12 49 24 55 71 41 69
Kawasaki Syndrome 72 49 24 3
Infantile Polyarteritis 53 71 69
Kd 53 24 3
Acute Febrile Mucocutaneous Lymph Node Syndrome 24 28
Kawasaki Disease, Susceptibility to 53 13
Acute Febrile Mucocutaneous Lymph Node Syndrome [mcls] 12
Acute Febrile Mcls 12
Kawasaki's Disease 12
Mlns 12
Kwd 71

Characteristics:

Orphanet epidemiological data:

55
kawasaki disease
Inheritance: Multigenic/multifactorial; Age of onset: Adolescent,Adult,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:



Summaries for Kawasaki Disease

OMIM : 53 Kawasaki disease is an acute, self-limited vasculitis of infants and children characterized by prolonged fever unresponsive to antibiotics, polymorphous skin rash, erythema of the oral mucosa, lips, and tongue, erythema of the palms and soles, bilateral conjunctival injection, and cervical lymphadenopathy (Kawasaki, 1967). Coronary artery aneurysms develop in 15 to 25% of those left untreated (11,12:Kato et al., 1975, 1996), making Kawasaki disease the leading cause of acquired heart disease among children in developed countries. Treatment with intravenous immunoglobulin (IVIG) abrogates the inflammation in approximately 80% of affected individuals and reduces the aneurysm rate to less than 5%. Cardiac sequelae of the aneurysms include ischemic heart disease, myocardial infarction, and sudden death. Epidemiologic features such as seasonality and clustering of cases suggested an infectious trigger, although no pathogen had been isolated. Several lines of evidence suggested the importance of genetic factors in disease susceptibility and outcome. First, the incidence of Kawasaki disease is 10 to 20 times higher in Japan than in Western countries (Cook et al., 1989). Second, the risk of Kawasaki disease in sibs of affected children is 10 times higher than in the general population, and the incidence of Kawasaki disease in children born to parents with a history of Kawasaki disease is twice as high as that in the general population (Fujita et al., 1989; Uehara et al., 2003). Hata and Onouchi (2009) reviewed current knowledge on Kawasaki disease, including epidemiology, genomewide linkage analysis, and molecular genetics. (611775)

MalaCards based summary : Kawasaki Disease, also known as mucocutaneous lymph node syndrome, is related to vasculitis and coronary stenosis, and has symptoms including fever, congestion of ocular conjunctivae and reddening of lips. An important gene associated with Kawasaki Disease is ITPKC (Inositol-Trisphosphate 3-Kinase C), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Aspirin and Analgesics have been mentioned in the context of this disorder. Affiliated tissues include lymph node, heart and tongue, and related phenotypes are hematopoietic system and homeostasis/metabolism

UniProtKB/Swiss-Prot : 71 Kawasaki disease: An acute, self-limited vasculitis of infants and children characterized by prolonged fever unresponsive to antibiotics, polymorphous skin rash, erythema of the oral mucosa, lips, and tongue, erythema of the palms and soles, bilateral conjunctival injection, and cervical lymphadenopathy.

NIH Rare Diseases : 49 Kawasaki disease is a disease that involves inflammation of the blood vessels. It is typically diagnosed in young children, but older children and adults can also develop this condition. Kawasaki disease begins with a fever that lasts at least five days. Other classic symptoms may include red eyes, lips, and mouth; rash; swollen and red hands and feet; and swollen lymph nodes. Sometimes the disease affects the coronary arteries which carry oxygen-rich blood to the heart, which can lead to serious heart problems. Kawasaki disease occurs most often in people of Asian and Pacific Island descent. The cause of Kawasaki disease is unknown. An infection along with genetic factors may be involved. Treatment includes intravenous gamma globulin and high doses of aspirin in a hospital setting.Prognosis is generally very good, but in cases of heart complications it depends on the severity of the coronary disease.  Last updated: 3/9/2017

MedlinePlus : 40 Kawasaki disease is a rare childhood disease. It makes the walls of the blood vessels in the body become inflamed. It can affect any type of blood vessel, including the arteries, veins, and capillaries. No one knows what causes Kawasaki disease. Symptoms include High fever that lasts longer than 5 days Swollen lymph nodes in the neck A rash on the mid-section and genital area Red, dry, cracked lips and a red, swollen tongue Red, swollen palms of the hands and soles of the feet Redness of the eyes Kawasaki disease can't be passed from one child to another. There is no single test. To diagnose it, doctors look at the signs and symptoms. They may also use an echocardiogram or other tests. It is mainly treated with medicines. Rarely, medical procedures and surgery also may be used for children whose coronary arteries are affected. Kawasaki disease can't be prevented. However, most children who develop the disease fully recover - usually within weeks of getting signs and symptoms. Further problems are rare. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Kawasaki disease (KD), also known as Kawasaki syndrome, is an acute febrile illness of unknown cause that primarily affects children younger than 5 years of age. The disease was first described in Japan by Tomisaku Kawasaki in 1967, and the first cases outside of Japan were reported in Hawaii in 1976. Clinical signs include fever, rash, swelling of the hands and feet, irritation and redness of the whites of the eyes, swollen lymph glands in the neck, and irritation and inflammation of the mouth, lips, and throat.

Genetics Home Reference : 24 Kawasaki disease is a sudden and time-limited (acute) illness that affects infants and young children. Affected children develop a prolonged fever lasting several days, a skin rash, and swollen lymph nodes in the neck (cervical lymphadenopathy). They also develop redness in the whites of the eyes (conjunctivitis) and redness (erythema) of the lips, lining of the mouth (oral mucosa), tongue, palms of the hands, and soles of the feet.

Disease Ontology : 12 A lymphadenitis characterized by swelling of cervical lymph nodes in infants and young children and inflammation of medium-sized blood vessels located in body, has symptom fever, has symptom congestion of ocular conjunctivae, has symptom reddening of lips, has symptom reddening of oral cavity, has symptom protuberance of tongue papillae and has symptom edema of extremities.

PubMed Health : 59
About kawasaki disease: Kawasaki (KAH-wah-SAH-ke) disease is a rare childhood disease. It's a form of a condition called vasculitis (vas-kyu-LI-tis). This condition involves inflammation of the blood vessels.In Kawasaki disease, the walls of the blood vessels throughout the body become inflamed. The disease can affect any type of blood vessel in the body, including the arteries, veins, and capillaries.Sometimes Kawasaki disease affects the coronary arteries, which carry oxygen-rich blood to the heart. As a result, some children who have Kawasaki disease may develop serious heart problems.

Wikipedia : 72 Kawasaki disease, also known as mucocutaneous lymph node syndrome, is a disease in which blood vessels... more...

Related Diseases for Kawasaki Disease

Diseases related to Kawasaki Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 393)
# Related Disease Score Top Affiliating Genes
1 vasculitis 30.9 CCL2 CRP ELANE SELE SELL TNF
2 coronary stenosis 30.6 ALB CRP IL6
3 polyarteritis nodosa 30.4 CRP IL6 SELE
4 toxic shock syndrome 30.4 IL10 IL6 TNF
5 infective endocarditis 30.4 CRP FCGR2A IL6 TNF
6 myocarditis 30.4 IL6 NPPB TNF
7 arthritis 30.1 CCL2 IL10 IL6 MMP3 MMP9 TNF
8 uveitis 30.1 CCL2 IL10 TNF
9 capillary leak syndrome 30.1 ALB ELANE IL6
10 cardiogenic shock 30.1 CRP IL6 NPPB
11 hand, foot and mouth disease 30.0 IL10 IL6 NPPB
12 pericardial effusion 30.0 CRP IL6 NPPB
13 juvenile rheumatoid arthritis 30.0 CRP IL6 TNF
14 cholangitis 29.9 ALB CRP IL6 TNF
15 mouth disease 29.9 CRP IL10 IL6 TNF
16 hemorrhagic fever 29.9 ALB IL10 IL6 TNF
17 acute pyelonephritis 29.9 ALB CRP IL10 IL6
18 acquired immunodeficiency syndrome 29.8 ALB IL10 IL6 TNF
19 colitis 29.8 IL10 IL6 S100A12 TNF
20 ischemic heart disease 29.8 CCL2 CRP IL6 NPPB TNF
21 adult respiratory distress syndrome 29.7 ELANE IL10 IL6 TNF
22 dengue hemorrhagic fever 29.6 ALB FCGR2A IL10 IL6 TNF
23 leptospirosis 29.6 CCL2 CRP IL10 IL6 TNF
24 toxoplasmosis 29.6 IL10 IL6 MYD88 TNF
25 vascular disease 29.5 CCL2 CRP MMP9 SELE
26 heart disease 29.5 ALB CRP IL6 MMP3 NPPB TNF
27 endocarditis 29.4 ALB CRP FCGR2A HSPD1 IL10 IL6
28 pyelonephritis 29.3 ALB CCL2 CRP IL10 IL6 TNF
29 pneumonia 29.3 CCL2 CRP ELANE IL10 IL6 MBL2
30 arteries, anomalies of 29.2 ALB CCL2 CRP IL6 MMP9 NPPB
31 appendicitis 29.0 ALB CRP IL10 IL6 MMP9 TIMP1
32 psoriasis 29.0 CCL2 ELANE IL10 IL6 S100A12 SELE
33 meningitis 28.7 ALB CCL2 CRP FCGR2A IL10 IL6
34 rheumatoid arthritis 28.6 CCL2 CRP IL10 IL6 MMP3 S100A12
35 asthma 27.8 CCL2 ELANE IL10 IL6 MMP9 SELE
36 myocardial infarction 27.8 ALB CCL2 CRP IL10 IL6 MMP3
37 systemic lupus erythematosus 27.7 ALB BLK CCL2 CRP ELANE FCGR2A
38 macrophage activation syndrome 11.3
39 spinal and bulbar muscular atrophy, x-linked 1 11.2
40 yt blood group antigen 10.9
41 malignant hyperthermia 1 10.9
42 kniest dysplasia 10.9
43 aneurysm 10.7
44 punctate inner choroidopathy 10.6 IL10 TNF
45 scorpion envenomation 10.6 IL6 TNF
46 tropical endomyocardial fibrosis 10.6 IL10 TNF
47 rheumatoid nodulosis 10.6 MMP3 MMP9
48 cold agglutinin disease 10.6 CRP IL6
49 coronary artery aneurysm 10.6
50 diverticulitis 10.5 CRP MMP9 TNF

Graphical network of the top 20 diseases related to Kawasaki Disease:



Diseases related to Kawasaki Disease

Symptoms & Phenotypes for Kawasaki Disease

Clinical features from OMIM:

611775

Symptoms:

12
  • fever
  • congestion of ocular conjunctivae
  • reddening of lips
  • reddening of oral cavity
  • protuberance of tongue papillae
  • edema of extremities

Human phenotypes related to Kawasaki Disease:

55 31 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002829
2 fatigue 55 31 frequent (33%) Frequent (79-30%) HP:0012378
3 edema 55 31 frequent (33%) Frequent (79-30%) HP:0000969
4 fever 55 31 frequent (33%) Frequent (79-30%) HP:0001945
5 abdominal pain 55 31 frequent (33%) Frequent (79-30%) HP:0002027
6 diarrhea 55 31 frequent (33%) Frequent (79-30%) HP:0002014
7 nausea and vomiting 55 31 occasional (7.5%) Occasional (29-5%) HP:0002017
8 recurrent pharyngitis 55 31 hallmark (90%) Very frequent (99-80%) HP:0100776
9 ptosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000508
10 arthritis 55 31 frequent (33%) Frequent (79-30%) HP:0001369
11 proteinuria 55 31 hallmark (90%) Very frequent (99-80%) HP:0000093
12 cranial nerve paralysis 55 31 occasional (7.5%) Occasional (29-5%) HP:0006824
13 arrhythmia 55 31 occasional (7.5%) Occasional (29-5%) HP:0011675
14 hepatitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0012115
15 irritability 55 31 occasional (7.5%) Occasional (29-5%) HP:0000737
16 congestive heart failure 55 31 occasional (7.5%) Occasional (29-5%) HP:0001635
17 jaundice 55 31 occasional (7.5%) Occasional (29-5%) HP:0000952
18 migraine 55 31 occasional (7.5%) Occasional (29-5%) HP:0002076
19 leukocytosis 55 31 frequent (33%) Frequent (79-30%) HP:0001974
20 cheilitis 55 31 hallmark (90%) Very frequent (99-80%) HP:0100825
21 erythema 55 31 hallmark (90%) Very frequent (99-80%) HP:0010783
22 pericarditis 55 31 frequent (33%) Frequent (79-30%) HP:0001701
23 myocarditis 55 31 occasional (7.5%) Occasional (29-5%) HP:0012819
24 conjunctivitis 55 31 hallmark (90%) Very frequent (99-80%) HP:0000509
25 skin rash 55 31 hallmark (90%) Very frequent (99-80%) HP:0000988
26 meningitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001287
27 vasculitis 55 31 hallmark (90%) Very frequent (99-80%) HP:0002633
28 cholecystitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001082
29 lymphadenopathy 55 31 hallmark (90%) Very frequent (99-80%) HP:0002716
30 glossitis 55 31 frequent (33%) Frequent (79-30%) HP:0000206
31 interstitial pulmonary abnormality 55 31 occasional (7.5%) Occasional (29-5%) HP:0006530
32 abnormality of nail color 55 31 frequent (33%) Frequent (79-30%) HP:0100643
33 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0011658
34 aseptic leukocyturia 55 31 occasional (7.5%) Occasional (29-5%) HP:0100586
35 abnormality of the heart valves 55 Frequent (79-30%)
36 dilatation of the ascending aorta 55 Occasional (29-5%)
37 abnormal heart valve morphology 31 frequent (33%) HP:0001654
38 ascending tubular aorta aneurysm 31 occasional (7.5%) HP:0004970

UMLS symptoms related to Kawasaki Disease:


pruritus, exanthema, edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Kawasaki Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 MYD88 FCGR2A IL10 SELE IL6 SELL
2 homeostasis/metabolism MP:0005376 10.07 ELANE MYD88 IL10 SELE IL6 SELL
3 immune system MP:0005387 10.06 MYD88 FCGR2A IL10 SELE IL6 SELL
4 endocrine/exocrine gland MP:0005379 10.02 MYD88 IL10 IL6 ITPKC ALB BLK
5 neoplasm MP:0002006 9.61 MYD88 IL10 IL6 SELL ALB MMP9
6 respiratory system MP:0005388 9.23 MYD88 IL10 SELE IL6 SELL MMP9

Drugs & Therapeutics for Kawasaki Disease

PubMedHealth treatment related to Kawasaki Disease: 59

Medicines are the main treatment for Kawasaki disease. Rarely, children whose coronary (heart) arteries are affected may need medical procedures or surgery.The goals of treatment include:Reducing fever and inflammation to improve symptomsPreventing the disease from affecting the coronary arteries

Drugs for Kawasaki Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
2 Analgesics Phase 4,Phase 2
3 Fibrinolytic Agents Phase 4,Phase 2
4 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Phase 1
5 gamma-Globulins Phase 4,Phase 3,Phase 2,Phase 1
6 Cyclooxygenase Inhibitors Phase 4,Phase 2
7 Analgesics, Non-Narcotic Phase 4,Phase 2
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
10 Platelet Aggregation Inhibitors Phase 4,Phase 2
11 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
14 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
15 Antipyretics Phase 4,Phase 2
16 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
17
Infliximab Approved Phase 3,Phase 2,Phase 1 170277-31-3
18
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
19
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
20 Pharmaceutical Solutions Phase 3,Phase 2
21 Protective Agents Phase 3,Phase 1
22 Autonomic Agents Phase 3,Phase 1
23 Prednisolone acetate Phase 3
24 glucocorticoids Phase 3
25 Methylprednisolone acetate Phase 3
26 Methylprednisolone Hemisuccinate Phase 3
27 Technetium Tc 99m Sestamibi Phase 3,Phase 1,Phase 2
28 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
29 Neuroprotective Agents Phase 3
30 Hormone Antagonists Phase 3
31 Dermatologic Agents Phase 3,Phase 2,Phase 1
32 Hormones Phase 3
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
34 Antiemetics Phase 3
35 Prednisolone hemisuccinate Phase 3
36 Prednisolone phosphate Phase 3
37 Radiopharmaceuticals Phase 3,Phase 1,Phase 2
38 Antineoplastic Agents, Hormonal Phase 3
39 alanine Nutraceutical Phase 3
40
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
41
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
42
Etanercept Approved, Investigational Phase 2 185243-69-0
43 tannic acid Approved, Nutraceutical Phase 2
44 Atorvastatin Calcium Phase 2,Phase 1 134523-03-8
45 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2,Phase 1
46 Anticholesteremic Agents Phase 2,Phase 1
47 Hypolipidemic Agents Phase 2,Phase 1
48 Antimetabolites Phase 2,Phase 1
49 Interleukin 1 Receptor Antagonist Protein Phase 2,Phase 1
50 Lipid Regulating Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 39)

# Name Status NCT ID Phase Drugs
1 Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease Completed NCT01524939 Phase 4 immunoglobulin G
2 A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Recruiting NCT02951234 Phase 4
3 Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial Completed NCT02298062 Phase 3 Infliximab;IVIG
4 Different Doses of IVIG for Kawasaki Disease Completed NCT02439996 Phase 3 IVIG (1g/kg,once);IVIG (1g/kg,twice);IVIG (2g/kg.once)
5 A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Completed NCT00162032 Phase 3 Sestamibi
6 Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Completed NCT00760435 Phase 3 Infliximab;Placebo
7 Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease Completed NCT01596335 Phase 3 TA-650;Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
8 Trial of Pulse Steroid Therapy in Kawasaki Disease--Pediatric Heart Network Completed NCT00132080 Phase 3 Steroids
9 Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders Completed NCT00157079 Phase 3
10 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
11 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
12 KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Recruiting NCT03065244 Phase 3 IVIG;Infliximab
13 A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Recruiting NCT03200561 Phase 3 Prednisolone
14 Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Unknown status NCT02114099 Phase 2 Atorvastatin
15 Anakinra and Kawasaki Disease Unknown status NCT02390596 Phase 2 Anakinra
16 Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study Unknown status NCT02219165 Phase 2 Intravenous human immunoglobulin;Albumin
17 Prevention of Coronary Aneurysms in Kawasaki Syndrome Completed NCT00000520 Phase 2 immunoglobulins, intravenous;aspirin
18 A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Completed NCT00162045 Phase 1, Phase 2 Technetium Tc99m Sestamibi
19 Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Recruiting NCT01431105 Phase 1, Phase 2 Atorvastatin
20 Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Recruiting NCT02179853 Phase 1, Phase 2 Anakinra
21 Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease Recruiting NCT01917721 Phase 2 Doxycycline;Standard care
22 Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Recruiting NCT03356769 Phase 2 Aspirin;AED;Placebo
23 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Recruiting NCT03174964 Phase 2 IVIg
24 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss Recruiting NCT03174951 Phase 2 IVIg
25 Etanercept in Kawasaki Disease Active, not recruiting NCT00841789 Phase 2 Etanercept;Placebo
26 Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Withdrawn NCT02980263 Phase 2 Canakinumab
27 Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease Withdrawn NCT00305201 Phase 2 pravastatin
28 Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging Unknown status NCT00861848 Phase 1
29 Infliximab (Remicade) for Patients With Acute Kawasaki Disease Completed NCT00271570 Phase 1 Infliximab (Remicade)
30 Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease Unknown status NCT02359643 Aspirin
31 Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease Completed NCT01440075
32 Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Completed NCT02317913
33 Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States Completed NCT00875641
34 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
35 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
36 Etiology Study of Kawasaki Disease Recruiting NCT00154596
37 Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD. Recruiting NCT02771288
38 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168
39 Measurement of Antibodies in Adults With a History of Kawasaki Disease Active, not recruiting NCT02853266

Search NIH Clinical Center for Kawasaki Disease

Cochrane evidence based reviews: mucocutaneous lymph node syndrome

Genetic Tests for Kawasaki Disease

Genetic tests related to Kawasaki Disease:

# Genetic test Affiliating Genes
1 Acute Febrile Mucocutaneous Lymph Node Syndrome 28 ITPKC

Anatomical Context for Kawasaki Disease

MalaCards organs/tissues related to Kawasaki Disease:

38
Lymph Node, Heart, Tongue, Eye, Skin, Endothelial, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Kawasaki Disease:

18
Body

Publications for Kawasaki Disease

Articles related to Kawasaki Disease:

(show top 50) (show all 1168)
# Title Authors Year
1
Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution. ( 29415012 )
2018
2
Retrospective observational study indicates that the Pediatric Assessment Triangle may suggest the severity of Kawasaki disease. ( 29385646 )
2018
3
Serum levels of C1q/tumor necrosis factor related protein-1 in children with Kawasaki disease. ( 29360808 )
2018
4
Kawasaki Disease. ( 29437127 )
2018
5
Cardiac function by Three Dimensional Speckle Tracking Imaging and Cytokines in Kawasaki Disease. ( 29350882 )
2018
6
Epidemiological Differences in Kawasaki Disease Between Past and Recent Periods: The distribution dynamism and its implications. ( 29359523 )
2018
7
Dengue-Triggered Kawasaki Disease: A Report of 2 Cases. ( 29424760 )
2018
8
Coronary Artery Aneurysm Formation: Kawasaki Disease versus Atherosclerosis. ( 29320319 )
2018
9
The association between oxidative stress and endothelial dysfunction in early childhood patients with Kawasaki disease. ( 29426283 )
2018
10
miRa89186, a serum microRNA, induces endothelial cell apoptosis by targeting SMAD6 in Kawasaki disease. ( 29344637 )
2018
11
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. ( 29386515 )
2018
12
Coronary artery aneurysm regression after Kawasaki disease and associated risk factors: a 3-year follow-up study in East China. ( 29330741 )
2018
13
Failure to Predict High-Risk Kawasaki Disease Patients in a Population-Based Study Cohort in Germany. ( 29406464 )
2018
14
Innate immune responses following Kawasaki disease and toxic shock syndrome. ( 29447181 )
2018
15
Atypical Kawasaki Disease Presenting with Hemiparesis and Aphasia: A Case Report. ( 29398757 )
2018
16
Macrophages and cytotoxic T cells infiltrate the destructed mitral tissue in Kawasaki disease. ( 29420247 )
2018
17
C-reactive protein and N-terminal pro-brain natriuretic peptide discrepancy: a differentiation of adenoviral pharyngoconjunctival fever from Kawasaki disease. ( 29441107 )
2018
18
MicroRNA-145-5p and microRNA-320a encapsulated in endothelial microparticles contribute to the progression of vasculitis in acute Kawasaki Disease. ( 29343815 )
2018
19
Putting Out the Fire in Acute Kawasaki Disease. ( 29395176 )
2018
20
Expression of Fc<gamma>Rs on monocytes among Kawasaki disease patients with coronary artery lesions. ( 28147297 )
2017
21
Coronary manifestations of Kawasaki Disease in computed tomography coronary angiography. ( 29426687 )
2017
22
Long-Term Prognosis for Patients with Kawasaki Disease Complicated by Large Coronary Aneurysm (diameter a8Y6 mm). ( 28765744 )
2017
23
The prevention of coronary arterial abnormalities in Kawasaki disease: AA meta-analysis of the corticosteroid effectiveness. ( 28927685 )
2017
24
CYP2E1 Gene Polymorphisms Related to the Formation of Coronary Artery Lesions in Kawasaki Disease. ( 28650933 )
2017
25
Association of Toll-like receptor 2-positive monocytes with coronary artery lesions and treatment nonresponse in Kawasaki disease. ( 28861111 )
2017
26
Relationship between vitamin D levels and intravenous immunoglobulin resistance in Kawasaki disease. ( 28861112 )
2017
27
Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker. ( 28417923 )
2017
28
A child with X-linked agammaglobulinemia and Kawasaki disease: an unusual association. ( 28365793 )
2017
29
Acute Complete Adult-onset Kawasaki Disease in a Middle-Aged Woman. ( 28903849 )
2017
30
Very Late Stent Migration Within a GiantA Coronary Aneurysm in a Patient WithA Kawasaki Disease: Assessment With Multidetector Computed Tomography. ( 28823775 )
2017
31
Correlation of HAMP gene polymorphisms and expression with the susceptibility and length of hospital stays in Taiwanese children with Kawasaki disease. ( 28881695 )
2017
32
Novel Risk Assessment Tool for Immunoglobulin-Resistance in Kawasaki Disease: Application Using a Random Forest Classifier. ( 28441265 )
2017
33
Simultaneous development of Kawasaki disease following acute human adenovirus infection in monozygotic twins: A case report. ( 28511718 )
2017
34
Male-specific association of the FCGR2A His167Arg polymorphism with Kawasaki disease. ( 28886140 )
2017
35
A Case of Kawasaki Disease With Concomitant Leptospirosis. ( 28804750 )
2017
36
Off-Pump Double Coronary Artery Bypass in a 14-Year-Old With Kawasaki Disease. ( 28935322 )
2017
37
Kawasaki Disease and Labyrinthitis: An Underdiagnosed Complication. ( 28417110 )
2017
38
Retrospective study of the impact of unrecognised Kawasaki disease, coronary aneurysm and ectasia. ( 28818354 )
2017
39
1,25-Dihydroxyvitamin D3 regulates T lymphocyte proliferation through activation of P53 and inhibition of ERK1/2 signaling pathway in children with Kawasaki disease. ( 28925469 )
2017
40
Epidemiology of Kawasaki Disease in Canada 2004 to 2014: Comparison of Surveillance Using Administrative Data vs Periodic Medical Record Review. ( 29395706 )
2017
41
Acute encephalopathy with biphasic seizures and late reduced diffusion in Kawasaki disease. ( 29265712 )
2017
42
Systemic-onset juvenile idiopathic arthritis and incomplete Kawasaki disease may belong to a single clinical syndrome within a spectrum of severity. ( 28980895 )
2017
43
Reaction of the BCG Scar in the Acute Phase of Kawasaki Disease in Mexican Children. ( 28498302 )
2017
44
Difficult diagnosis of Kawasaki disease in a patient with giant coronary artery aneurysms. ( 28895991 )
2017
45
Fever without a source: evolution of a diagnosis from Kawasaki disease to acute myelogenous leukaemia. ( 28478386 )
2017
46
Pulmonary presentation of Kawasaki disease-A diagnostic challenge. ( 28950425 )
2017
47
Computed tomography predict regression of coronary artery aneurysm in patients with Kawasaki disease. ( 28734587 )
2017
48
Coronary Stenosis after Kawasaki Disease: Size Matters. ( 29248184 )
2017
49
Adult onset Kawasaki disease presenting with acute epiglottitis findings. ( 29102400 )
2017
50
Z-score of Mitral Annular Plane Systolic Excursion is a Useful Indicator of Evaluation of Left Ventricular Function in Patients with Acute-Phase Kawasaki Disease. ( 28456832 )
2017

Variations for Kawasaki Disease

Expression for Kawasaki Disease

Search GEO for disease gene expression data for Kawasaki Disease.

Pathways for Kawasaki Disease

Pathways related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 BLK CCL2 CRP ELANE FCGR2A IL10
2
Show member pathways
13.36 CCL2 IL10 IL6 MMP3 MMP9 MYD88
3
Show member pathways
12.87 CCL2 IL6 MMP9 SELE TNF
4
Show member pathways
12.7 BLK IL6 MYD88 TIMP1 TNF
5
Show member pathways
12.59 CCL2 IL10 IL6 TIMP1 TNF
6 12.57 BLK CCL2 IL10 MYD88 TNF
7
Show member pathways
12.53 CCL2 IL10 IL6 MYD88 TNF
8
Show member pathways
12.34 ALB CCL2 CRP IL6 TNF
9
Show member pathways
12.33 CCL2 IL6 MMP3 MMP9 TNF
10
Show member pathways
12.25 FCGR2A IL10 MYD88 TNF
11 12.24 ELANE IL6 MMP3 MMP9
12 12.22 FCGR2A HSPD1 IL10 IL6 MYD88 TNF
13 12.18 HSPD1 IL10 IL6 TNF
14 12.09 CCL2 MMP9 SELE TNF
15 12.02 CCL2 FCGR2A IL6 MMP9 TNF
16 12 FCGR2A IL10 IL6 SELL TNF
17 11.92 CCL2 IL6 SELE TNF
18
Show member pathways
11.92 ELANE MMP3 MMP9 TIMP1 TNF
19 11.87 CCL2 IL6 MMP3 TNF
20 11.86 CCL2 MMP3 MMP9 TIMP1
21 11.83 CCL2 IL6 MMP3 MMP9 SELE TNF
22
Show member pathways
11.8 CRP IL6 TIMP1
23 11.77 IL10 IL6 MYD88 TNF
24 11.75 IL10 IL6 SELL TNF
25 11.69 FCGR2A IL10 IL6 TNF
26 11.65 CCL2 IL6 MMP9 TIMP1 TNF
27 11.64 MMP3 MMP9 TIMP1
28
Show member pathways
11.63 IL6 MMP3 MMP9 SELE TNF
29 11.6 HSPD1 IL6 MYD88 TNF
30 11.59 FCGR2A IL10 MBL2
31 11.56 CCL2 IL10 IL6 MMP3 MMP9 TIMP1
32 11.49 CCL2 IL10 IL6 TIMP1 TNF
33 11.45 BLK ELANE IL6 MMP9 TNF
34 11.36 IL10 IL6 TNF
35 11.34 CCL2 IL6 MMP9
36 11.28 IL10 IL6 TNF
37 11.25 ELANE MMP3 MMP9 SELE SELL
38 11.2 CCL2 IL10 IL6 TNF
39 11.18 CCL2 MMP9 MYD88 TIMP1
40 11.1 IL10 IL6 MYD88 SELE TNF
41 11.05 CRP IL6 TNF
42 10.79 CCL2 IL10 IL6 MYD88 SELE TNF

GO Terms for Kawasaki Disease

Cellular components related to Kawasaki Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 ALB CCL2 CRP ELANE IL10 IL6
2 extracellular space GO:0005615 9.47 ALB CCL2 CRP ELANE HSPD1 IL10

Biological processes related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.92 ELANE IL10 MYD88 SELE
2 negative regulation of apoptotic process GO:0043066 9.91 ALB HSPD1 IL10 IL6 MMP9 MYD88
3 leukocyte migration GO:0050900 9.89 ELANE MMP9 SELE SELL TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 IL6 MYD88 S100A12 TNF
5 defense response to bacterium GO:0042742 9.88 ELANE IL10 MBL2 S100A12 TNF
6 cellular response to lipopolysaccharide GO:0071222 9.87 CCL2 IL10 IL6 TNF
7 regulation of inflammatory response GO:0050727 9.83 MYD88 SELE TNF
8 response to glucocorticoid GO:0051384 9.82 IL10 IL6 TNF
9 positive regulation of MAP kinase activity GO:0043406 9.8 ELANE S100A12 TNF
10 humoral immune response GO:0006959 9.79 CCL2 IL6 TNF
11 monocyte chemotaxis GO:0002548 9.77 CCL2 IL6 S100A12
12 extracellular matrix disassembly GO:0022617 9.76 ELANE MMP3 MMP9 TIMP1
13 acute-phase response GO:0006953 9.75 CRP IL6 MBL2
14 lipopolysaccharide-mediated signaling pathway GO:0031663 9.71 CCL2 MYD88 TNF
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.71 ELANE IL6 MYD88 TNF
16 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.69 IL10 MMP9 TNF
17 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
18 leukocyte migration involved in inflammatory response GO:0002523 9.65 ELANE SELE
19 opsonization GO:0008228 9.65 CRP MBL2
20 positive regulation of chemokine biosynthetic process GO:0045080 9.64 MYD88 TNF
21 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.64 ELANE TNF
22 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.63 IL10 TIMP1
23 endothelial cell apoptotic process GO:0072577 9.63 IL10 TNF
24 positive regulation of interleukin-6 production GO:0032755 9.62 HSPD1 IL6 MYD88 TNF
25 response to peptidoglycan GO:0032494 9.61 IL6 MYD88
26 leukocyte tethering or rolling GO:0050901 9.61 SELE SELL TNF
27 negative regulation of cytokine secretion involved in immune response GO:0002740 9.6 IL10 TNF
28 receptor biosynthetic process GO:0032800 9.56 IL10 TNF
29 inflammatory response GO:0006954 9.56 CCL2 CRP IL10 IL6 MYD88 S100A12
30 negative regulation of chemokine biosynthetic process GO:0045079 9.55 ELANE IL6
31 defense response to Gram-positive bacterium GO:0050830 9.55 CRP IL6 MBL2 MYD88 TNF
32 negative regulation of lipid storage GO:0010888 9.43 CRP IL6 TNF
33 negative regulation of growth of symbiont in host GO:0044130 9.02 ELANE IL10 MBL2 MYD88 TNF
34 neutrophil degranulation GO:0043312 10.06 ELANE FCGR2A MMP9 S100A12 SELL
35 regulation of receptor activity GO:0010469 10 CCL2 IL10 IL6 NPPB TIMP1 TNF

Molecular functions related to Kawasaki Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.71 ELANE MBL2 MMP3 MMP9
2 receptor binding GO:0005102 9.65 BLK CCL2 MBL2 MYD88 NPPB
3 protein binding GO:0005515 9.6 ALB BLK CCL2 CRP ELANE FCGR2A
4 endopeptidase activity GO:0004175 9.54 ELANE MMP3 MMP9
5 protease binding GO:0002020 9.46 ELANE SELL TIMP1 TNF
6 cytokine activity GO:0005125 9.35 CCL2 IL10 IL6 TIMP1 TNF
7 oligosaccharide binding GO:0070492 9.32 SELE SELL

Sources for Kawasaki Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....